ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.985
-0.045 (-0.89%)
Mar 19, 2026, 12:40 PM CET
Market Cap17.76M -74.7%
Revenue (ttm)10.85M +36.8%
Net Income-45.17M
EPS-17.71
Shares Out3.53M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,448
Average Volume24,185
Open4.830
Previous Close5.030
Day's Range4.810 - 4.995
52-Week Range4.810 - 34.200
Beta2.37
RSI18.20
Earnings DateFeb 19, 2026

About STO:EXPRS2

ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a huma... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 20
Stock Exchange Nasdaq Stockholm
Ticker Symbol EXPRS2
Full Company Profile

Financial Performance

In 2024, STO:EXPRS2's revenue was 7.83 million, a decrease of -11.07% compared to the previous year's 8.80 million. Losses were -36.04 million, -60.57% less than in 2023.

Financial Statements